

Declaration of Interest and Declaration of Confidentiality of ISoP Advisory Board members

This form consists of two parts, your personal details with biography, and the Public Declaration of Interests. It applies to the Executive Committee (EC) and Advisory Board members of the International Society of Pharmacovigilance.

Both parts of the form should be fully completed, signed, dated and return electronically to administration@isoponline.org with a short biography.

The Declaration of Interest and the biography will be published on isoponline.

1 Personal Details (please enclose your biography)

First Name	Gianluca
Surname	Trifirò
Organisation	University of Messina
Country	Italy

I enclose my biography

I, Gianluca Trifirò, do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2 Public Declaration of Interests

If you have interests to declare, please do so under the relevant questions. If you have no interests to declare, please indicate that the appropriate field is non-applicable. Please specify the interests that you currently have or have had in the past 5 years.

Title/Function	Period of activity (within past 5 years)	Company* or organisation**	Description of the activity
1. Employment with a pharmaceutical company or an organisation			
2. Consultancy, advice or services with a pharmaceutical company or an organisation (including training)			
Advisory Board	25 September 2019	Sanofi Genzyme	Participation to one day advisory board on sarilumab for treating polymyalgia

			rheumatica
Advisory Board	17 April 2019	Abbvie	Participation to one day advisory board on drugs for myeloma
Seminar	8 March 2019	Astrazeneca	Lecture on asthma drug
Advisory Board	18 January 2019	Sanofi	Participation to mock up negotiation on sarilumab
Consultant	1 Jan – 31 Dec 2018	Otsuka	To provide on demand advice on methodological issues concerning clinical studies
Seminar	27 November 2018	Mylan	Lecture on biosimilars
Advisory Board	10 October 2018	GSK	Participation to one day advisory board on drugs for COPD
Advisory Board	20-21 June 2017	Biogen	Participation to two days advisory board on daclizumab
Advisory Board	16 January 2017	Ipsen	Participation to one day advisory Board on metastatic renal carcinoma
Advisory Board	23 November 2016	Novartis	Participation to one day Advisory Board on digital tools applied in respiratory Disease
Advisory Board	13 June 2016	Bayer	Participation to one day Advisory Board on Data Mining in general practice
Seminar	September 2015	Hospira	Seminar on biosimilars in the context of e-learning course
3. Strategic advisory role, member of professional societies, affiliation or equivalent structure			
4. Grant / research funding including sponsorships, fellowships, non-monetary support			
I coordinate a team of pharmacoepidemiology at the University of Messina which received unconditional grants for observational studies in the last 5 year as itemized below			
Grant at Univ. Messina	2018-2019	PTC Therapeutics	Observational study on Duchenne muscular dystrophy epidemiology using healthcare databases
Grant at Univ. Messina	2018-2019	AstraZeneca	Observational study on antidiabetic drugs using healthcare databases
Grant at Univ. Messina	2017	Amgen	Observational study on drugs for treating osteoporosis using healthcare databases
Grant at Univ. Messina	2016	IBSA	Observational study on levotiroxine using healthcare

			databases
5. Financial interests, direct shares of a pharmaceutical company, compensation, fees, honoraria (excluded investment trust without direct influence on shares)			
6. Patents			
7. Investigator (in a pharmaceutical industry instigated/sponsored clinical trial)			
8. Family member interest			
9. Any other interests or facts			
Since 2016 I coordinate a Master program at the University of Messina which has received unconditional funding by several pharmaceutical companies			

** Pharmaceutical company (includes supply or service companies which contribute to the research, development production and maintenance of a medicinal product)*

*** An organisation includes governmental, international or non-profit organisations (outside ISoP)*

Should there be any change to the information provided above due to the fact that I acquire additional interests, I shall promptly notify ISoP and complete a new Declaration of Interests detailing the changes.

I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the ISoP website.

Signature:

Date: 26 November 2019

